Does early intensive multifactorial treatment reduce total cardiovascular burden in individuals with screen‐detected diabetes? Findings from the ADDITION‐Europe cluster‐randomized trial
Year: 2012
Type: article
Study design: Clinical Trial
Abstract: AIMS: To describe the total cardiovascular burden (cardiovascular morbidity or mortality, revascularization or non-traumatic amputation) in individuals with screen-detected diabetes in the ADDITION-Europe trial and to quantify the impact of the intervention on multiple cardiovascular events over 5 years. METHODS: In a pragmatic, cluster-randomized, parallel-group trial in four centres (Denmark; Cambridge, UK; the Netherlands; and Leicester, UK), 343 general practices were randomized to screening plus routine care (n = 1379 patients), or screening and promotion of target-driven, intensive treatment of multiple risk factors (n = 1678). We estimated the effect of the intervention on multiple cardiovascular events after diagnosis of diabetes using the Wei, Lin and Weissfeld method. RESULTS: Over 5.3 years, 167 individuals had exactly one cardiovascular event, 53 exactly two events, and 18 three or more events. The incidence rates (95% CI) of first events and any event per 1000 person-years were 14.6 (12.8-16.6) and 20.4 (18.2-22.6), respectively. There were non-significant reductions in the risk of a first (hazard ratio 0.83, 95% CI 0.65-1.05) and second primary endpoint (hazard ratio 0.70, 95% CI 0.43-1.12). The overall average hazard ratio for any event was 0.77 (95% CI 0.58-1.02). CONCLUSIONS: Early intensive multifactorial treatment was not associated with a significant reduction in total cardiovascular burden at 5 years. Focusing on first events in cardiovascular disease prevention trials underestimates the total cardiovascular burden to patients and the health service.
Source: Diabetic Medicine
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,870
Funders: Pfizer, GlaxoSmithKline, Strategiske Forskningsråd, Aarhus Universitet, Sundhed og Sygdom, Det Frie Forskningsråd, Wellcome Trust, National Institute for Health and Care Research, Aarhus Universitets Forskningsfond, Novo Nordisk, Novo Nordisk Fonden, Servier, Medical Research Council, Health Technology Assessment Programme
Awards: Anglo-Danish-Dutch study of Intensive Treatment of people with Newly diagnosed diabetes in primary care (ADDITION) - effects on cardiovascular events at five years, G2289583185, Embedding structured self management education programmes for Type 2 diabetes in a multi-ethnic primary care setting: developing key areas to support a NIHR Programme Grant submission, A community based primary prevention programme for Type 2 Diabetes integrating identification, lifestyle intervention and community services for prevention., G6514246486, Reducing the burden of type 2 diabetes: translating epidemiology and behavioural science into preventive action, G7700387550
OpenAlex ID: W1521253260
